Atrandi Biosciences is breaking new ground in high-throughput analysis technologies. Providing simple-to-adopt and easy-to-use droplet microfluidics and high-throughput screening (HTS) workflows. Droplet microfluidics technology is at the core of our products and provides an unmatched platform for exploring the complexity of biology in a high-throughput manner. Droplet microfluidics enables compartmentalizing molecular biology reactions into millions of pico-liter droplets, empowering you to study biological samples at the resolution of single cells and single molecules. Our work is at the intersection of life sciences, engineering, and machine learning. We deliver elegant solutions and novel tools for groundbreaking high-throughput research by integrating different technologies.
$25M sweet spot round size
2016
$25M
from 2 investors over 1 rounds
Atrandi Biosciences raised $25M on March 18, 2025
Investors: Lux Capital and + 4 Other investors